Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:20:47 ON 16 FEB 2009

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 20:20:59 ON 16 FEB 2009

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2009 HIGHEST RN 1106670-14-7
DICTIONARY FILE UPDATES: 15 FEB 2009 HIGHEST RN 1106670-14-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\105071596.str



chain nodes :
7 8 9 10
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
1-7 4-13 7-8 8-9 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-13 5-6 7-8 8-9
exact bonds :
1-7 9-10
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :

containing 1 : 13 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 20:21:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 65 TO ITERATE

100.0% PROCESSED 65 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 817 TO 1783
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 20:21:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1109 TO ITERATE

100.0% PROCESSED 1109 ITERATIONS 31 ANSWERS
SEARCH TIME: 00.00.05

L3 31 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 20:21:49 ON 16 FEB 2009

FILE COVERS 1907 - 16 Feb 2009 VOL 150 ISS 8
FILE LAST UPDATED: 15 Feb 2009 (20090215/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:300395 CAPLUS
DOCUMENT NUMBER: 142:355054
TITLE: Preparation of amide derivatives as inhibitors of histone deacetylase
INVENTOR(S): Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie; Vaisburg, Arkadii; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.
PATENT ASSIGNEE(S): Methylgene, Inc., Can.
SOURCE: PCT Int. Appl., 559 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030705	A1	20050407	WO 2004-US31591	20040924
WO 2005030705	A9	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276337	A1	20050407	AU 2004-276337	20040924
CA 2539117	A1	20050407	CA 2004-2539117	20040924
EP 1663953	A1	20060607	EP 2004-789074	20040924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1882529	A	20061220	CN 2004-80034571	20040924
JP 2007506785	T	20070322	JP 2006-528279	20040924
US 20080132459	A1	20080605	US 2006-574088	20060323
KR 2006065730	A	20060614	KR 2006-707812	20060421
JP 2008094847	A	20080424	JP 2007-281356	20071030

PRIORITY APPLN. INFO.: US 2003-505884P P 20030924
US 2003-532973P P 20031229
US 2004-561082P P 20040409
JP 2006-528279 A3 20040924
WO 2004-US31591 W 20040924

OTHER SOURCE(S): CASREACT 142:355054; MARPAT 142:355054
GI



I



II

AB Title compds. I [Ar1 = (un)saturated-, (un)substituted-mono or fused poly-cyclic hydrocarbyl optionally containing 1-4 heteroatoms per ring; R1 = (un)substituted-mono-, -bi-, -tri-cyclic-aryl or -heteroaryl; R2, R3, and R4 independently = H, halo, amino, etc.; R5 and R6 independently = H, alkyl, aryl, etc.; x = 0-1; Y = any pharmaceutically acceptable chemical moiety consisting of 1 to 50 atoms with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylase. Thus, e.g., II was prepared by Suzuki coupling of 2-bromo-2-nitro-phenylamine (preparation given) with 2-thiopheneboronic acid followed by carbonylation with 4-[3,4-dimethoxy-(phenylamino)-methyl]benzoic acid (preparation given) and subsequent reduction The inhibitory capability of I towards antiproliferative activity of histone deacetylase enzyme was evaluated using 3-[4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium] bromide (MTT) assay and it revealed that certain compds. of the invention had MTT IC 50 values in the range of below 1 up to 20 μM. I as histone deacetylase inhibitors should prove useful in the treatment of diseases such as, but not limited to, cell proliferative disease, protozoal disease, and fungal disease.

IT 603953-70-4P 603953-75-9P 603953-89-5P
603954-00-3P 603954-07-0P 603954-08-1P
603954-09-2P 603954-10-5P 603954-11-6P
603954-12-7P 603954-13-8P 603954-14-9P
603954-15-0P 603954-87-6P 849237-01-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amide derivs. as inhibitors of histone deacetylase)

RN 603953-70-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603953-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603953-89-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[([1,1'-biphenyl]-4-ylsulfonyl)amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-00-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-07-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[3'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-08-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[2-(3-furanyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-09-2 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(3'-methyl[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-10-5 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[[2-(3-thienyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-11-6 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(2'-methyl[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-12-7 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(3'-methoxy[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-87-6 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 849237-01-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[(3R,4R)-3-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-13-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[[2-(2-benzofuranyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-14-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[[4'-(dimethylamino)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-15-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(4'-methoxy[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:300394 CAPLUS
DOCUMENT NUMBER: 142:373563
TITLE: Preparation of amide derivatives as inhibitors of histone deacetylase
INVENTOR(S): Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie; Vaisburg, Arkadii; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.
PATENT ASSIGNEE(S): Methylgene, Inc., Can.
SOURCE: PCT Int. Appl., 389 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030704	A1	20050407	WO 2004-US31590	20040924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2008094847	A	20080424	JP 2007-281356	20071030

PRIORITY APPLN. INFO.: US 2003-505884P P 20030924
US 2003-532973P P 20031229
US 2004-561082P P 20040409
JP 2006-528279 A3 20040924

OTHER SOURCE(S): CASREACT 142:373563; MARPAT 142:373563
GI

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB Title compds. I [Ar1 = (un)saturated-, (un)substituted-mono or fused poly-cyclic hydrocarbyl optionally containing 1-4 heteroatoms per ring; R1 = (un)substituted-mono-, -bi-, -tri-cyclic-aryl or -heteroaryl; R2, R3, and R4 independently = H, halo, amino, etc.; R5 and R6 independently = H, alkyl, aryl, etc.; x = 0-1; Y = any pharmaceutically acceptable chemical moiety consisting of 1 to 50 atoms with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylase. Thus, e.g., II was prepared by Suzuki coupling of 2-bromo-2-nitro-phenylamine (preparation given) with 2-thiopheneboronic acid followed by carbonylation with 4-[3,4-dimethoxy-(phenylamino)-methyl]benzoic acid (preparation given) and subsequent reduction The inhibitory capability of I towards antiproliferative activity of histone deacetylase enzyme was evaluated using 3-[4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium] bromide (MTT) assay and it revealed that certain compds. of the invention had MTT IC 50 values in the range of below 1 up to 20 μM. I as histone deacetylase inhibitors should prove useful in the treatment of diseases such as, but not limited to, cell proliferative disease, protozoal disease, and fungal disease.

IT 603953-70-4P 603953-75-9P 603953-89-5P
603954-00-3P 603954-07-0P 603954-08-1P
603954-09-2P 603954-10-5P 603954-11-6P
603954-12-7P 603954-13-8P 603954-14-9P
603954-15-0P 603954-87-6P 849237-01-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amide derivs. as inhibitors of histone deacetylase)

RN 603953-70-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603953-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603953-89-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[([1,1'-biphenyl]-4-ylsulfonyl)amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-00-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-07-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[3'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-08-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[2-(3-furanyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-09-2 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(3'-methyl[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-10-5 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[2-(3-thienyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-11-6 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(2'-methyl[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-12-7 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(3'-methoxy[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 603954-13-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[[2-(2-benzofuranyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-14-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[[4'-(dimethylamino)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-15-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(4'-methoxy[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-87-6 CAPLUS

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 849237-01-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[(3R,4R)-3-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:737724 CAPLUS
DOCUMENT NUMBER: 139:276820
TITLE: Preparation of sulfonylaminopiperidine derivatives as inhibitors of histone deacetylase
INVENTOR(S): Van Emelen, Kristof; Backx, Leo Jacobus Jozef; Van Brandt, Sven Franciscus Anna; Angibaud, Patrick Rene; Pilatte, Isabelle Noelle Constance; Verdonck, Marc Gustaaf Celine; De Winter, Hans Louis Jos
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076401	A1	20030918	WO 2003-EP2517	20030311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476186	A1	20030918	CA 2003-2476186	20030311
AU 2003209727	A1	20030922	AU 2003-209727	20030311
AU 2003209727	B2	20081016		
EP 1485354	A1	20041215	EP 2003-743874	20030311
EP 1485354	B1	20080528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007599	A	20050201	BR 2003-7599	20030311
CN 1642912	A	20050720	CN 2003-805951	20030311
CN 1305850	C	20070321		
JP 2005526763	T	20050908	JP 2003-574622	20030311
NZ 534771	A	20060428	NZ 2003-534771	20030311
CN 101007803	A	20070801	CN 2007-10005212	20030311
AT 396971	T	20080615	AT 2003-743874	20030311
ES 2306880	T3	20081116	ES 2003-743874	20030311
TW 280958	B	20070511	TW 2003-92105280	20030312
MX 2004007776	A	20041015	MX 2004-7776	20040811
IN 2004DN02521	A	20070112	IN 2004-DN2521	20040830
US 20050171347	A1	20050804	US 2004-507159	20040908
NO 2004004224	A	20041005	NO 2004-4224	20041005
PRIORITY APPLN. INFO.:			US 2002-363799P P	20020313
			WO 2002-EP14481 A	20021218
			WO 2002-EP14081 A	20021218
			WO 2002-EP14833 A	20021223
			CN 2003-805921 A3	20030311

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
WO 2003-EP2517 W 20030311

OTHER SOURCE(S): MARPAT 139:276820
GI



I



II

AB The title compds. I [Q, X, Y, Z = N, (un)substituted CH; R1 = (un)substituted CONH2, NHCHO, COalkanediylSH, CONHOH, NHCOC:NHOH or other Zn-chelating group; R2 = H, halogen, OH, amino, NO2, alkyl, alkoxy, CF3, dialkylamino, NHOH, naphthalenylsulfonylpyrazinyl; R3 = H, aryl; R4 = H, OH, amino, (un)substituted alkyl, alkoxy, CONH2, CO2H; R5 = H, alkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, dialkylaminoalkyl, aryl; A = (un)substituted Ph, cyclohexyl, heterocyclic, heteroaryl, naphthyl; n = 0-3; p = 0-4] were prepared for use as histone deacetylase inhibitors in the treatment of proliferative diseases. Thus, the sulfonylaminopiperidine II was prepared from Et 4-aminopiperidine-1-carboxylate, 2-naphthalenesulfonyl chloride, and Et 2-methylsulfonylpyrimidine-5-carboxylate in 6 steps. II had pIC50 for inhibition of histone deacetylase of 6.523 and for antiproliferative activity against A2780 cells of 5.277.

IT 603953-70-4P 603953-74-8P 603953-75-9P
603953-89-5P 603953-95-3P 603954-00-3P
603954-07-0P 603954-08-1P 603954-09-2P
603954-10-5P 603954-11-6P 603954-12-7P
603954-13-8P 603954-14-9P 603954-15-0P
603954-87-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminopiperidine derivs. as inhibitors of histone deacetylase)

RN 603953-70-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603953-74-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[(3S,4S)-3-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 603953-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603953-89-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[([1,1'-biphenyl]-4-ylsulfonyl)amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603953-95-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[3-[(2-naphthalenylsulfonyl)amino]propyl]-1-piperidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 603953-94-2
CMF C23 H27 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 603954-00-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-07-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[3'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-08-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[2-(3-furanyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-09-2 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(3'-methyl[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-10-5 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[2-(3-thienyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-11-6 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(2'-methyl[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-12-7 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(3'-methoxy[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 603954-13-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[[2-(2-benzofuranyl)phenyl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-14-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[[4'-(dimethylamino)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]-N-hydroxy- (CA INDEX NAME)



RN 603954-15-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[(4'-methoxy[1,1'-biphenyl]-2-yl)sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 603954-87-6 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-58-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[[[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (CA INDEX NAME)



RN 603954-63-8 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-[4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 603954-66-1 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-[(3S,4S)-3-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-[[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)



IT 603954-56-9DP, polymer-supported 603954-57-0P
603954-58-1P 603954-63-8P 603954-66-1P
603954-67-2P 603954-70-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonylaminopiperidine derivs. as inhibitors of histone deacetylase)
RN 603954-56-9 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-[4-[[[(2-iodophenyl)sulfonyl]amino]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 603954-57-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-[4-[[[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]sulfonyl]amino]methyl]-1-piperidinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 603954-67-2 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-[4-hydroxy-4-[[(2-naphthalenylsulfonyl)amino]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 603954-70-7 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-[4-[3-[(2-naphthalenylsulfonyl)amino]propyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      18.42     204.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.46      -2.46

STN INTERNATIONAL LOGOFF AT 20:23:40 ON 16 FEB 2009
```